

CITATION REPORT

List of articles citing

Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists
Antibody-Drug Conjugate Working Group position paper

DOI: 10.4155/bio.13.38
Bioanalysis, 2013, 5, 997-1006.

Source: <https://exaly.com/paper-pdf/56718161/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
136	Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. 2013 , 67, 382-91		32
135	Validation of an immunoassay to selectively quantify the naked antibody of a new Antibody Drug Conjugate--SAR566658--for pharmacokinetic interpretation improvement. 2013 , 396, 140-6		8
134	Bioanalysis special focus issue on antibody-drug conjugates. <i>Bioanalysis</i> , 2013 , 5, 981-3	2.1	17
133	Conference report: hot topics in antibody-drug conjugate development. <i>Bioanalysis</i> , 2013 , 5, 2989-93	2.1	
132	2013 White Paper on recent issues in bioanalysis: 'hybrid'--the best of LBA and LCMS. <i>Bioanalysis</i> , 2013 , 5, 2903-18	2.1	55
131	Bioanalysis annual round-up: the bioanalysis editorial team is delighted to welcome you to this mid-year round-up. <i>Bioanalysis</i> , 2013 , 5, 2227-31	2.1	
130	Bioanalysis of antibodydrug conjugates. 2013 , 6-16		
129	ISR: background, evolution and implementation, with specific consideration for ligand-binding assays. <i>Bioanalysis</i> , 2014 , 6, 393-402	2.1	7
128	Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies. 2014 , 6, 859-70		39
127	2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input). <i>Bioanalysis</i> , 2014 , 6, 3237-49	2.1	36
126	The 'blended' bioanalytical laboratory: the marriage of antibody- and instrument-based methods and expertise. <i>Bioanalysis</i> , 2014 , 6, 717-9	2.1	
125	Resolution of matrix interference: quantitative and quasi-quantitative ligand-binding assays case studies. <i>Bioanalysis</i> , 2014 , 6, 1093-101	2.1	4
124	Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. 2014 , 42, 1914-20		63
123	Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates. 2014 , 28, 383-91		17
122	Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding assays. <i>Bioanalysis</i> , 2014 , 6, 185-98	2.1	31
121	Clinical pharmacology and assay consideration for characterizing pharmacokinetics and understanding efficacy and safety of antibodydrug conjugates. 2015 , 36-55		3
120	Application of ligand-binding assays for bioanalysis of antibodydrug conjugates. 2015 , 20-35		

119	Analytical assays for antibody-drug conjugate selection and development. 2015 , 56-68		
118	Bioanalytical Assay for Characterization of Antibody-Drug Conjugates (ADCs). 2015 , 97-115		1
117	Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development. <i>Pharmaceutical Research</i> , 2015 , 32, 3508-25	4.5	37
116	Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance. 2015 , 17, 277-88		91
115	Recommendations for validation of LC-MS/MS bioanalytical methods for protein biotherapeutics. 2015 , 17, 1-16		127
114	Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates. <i>Pharmaceutical Research</i> , 2015 , 32, 3470-9	4.5	71
113	Biotransformation and stability of antibody-drug conjugates: payload metabolism and linker cleavage delineation. <i>Bioanalysis</i> , 2015 , 7, 1319-23	2.1	7
112	Highly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques. 2015 , 140, 6175-94		31
111	An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates. <i>Pharmaceutical Research</i> , 2015 , 32, 3584-92	4.5	4
110	Highlights from the 2014 Applied Pharmaceutical Analysis conference. <i>Bioanalysis</i> , 2015 , 7, 9-13	2.1	
109	Antibody-Drug Conjugates. 2015 ,		6
108	Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC-MS/MS approach: Assay development, validation, and a case study. 2015 , 1002, 54-62		44
107	In vivo biotransformations of antibody-drug conjugates. <i>Bioanalysis</i> , 2015 , 7, 1649-64	2.1	34
106	Bioanalysis of antibody-drug conjugates. <i>Bioanalysis</i> , 2015 , 7, 1559-60	2.1	7
105	An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study. <i>Bioanalysis</i> , 2015 , 7, 1569-82	2.1	25
104	Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays. <i>Bioanalysis</i> , 2015 , 7, 1605-17	2.1	20
103	Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates. <i>Bioanalysis</i> , 2015 , 7, 1583-604	2.1	26
102	Integration of bioanalytical measurements using PK-PD modeling and simulation: implications for antibody-drug conjugate development. <i>Bioanalysis</i> , 2015 , 7, 1633-48	2.1	14

101	Approaches to Interchain Cysteine-Linked ADC Characterization by Mass Spectrometry. 2015 , 12, 1774-83		29
100	Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates. 2015 , 54, 81-93		33
99	Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. 2015 , 17, 35-43		49
98	An Overall Comparison of Small Molecules and Large Biologics in ADME Testing. 2016 , 4, 1		20
97	. 2016 ,		4
96	Boston Society's 11th Annual Applied Pharmaceutical Analysis conference. <i>Bioanalysis</i> , 2016 , 8, 259-64	2.1	1
95	Immunogenicity and its effect on pharmacokinetics of biotherapeutics. 2016 , 68-82		
94	Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016 , 5, 665-673	4.5	8
93	Current Issues in Ligand Binding Assay Bioanalysis. 2016 ,		
92	Characterization of antibody-drug conjugates by mass spectrometry: advances and future trends. 2016 , 21, 850-5		33
91	Calculated conjugated payload from immunoassay and LC-MS intact protein analysis measurements of antibody-drug conjugate. <i>Bioanalysis</i> , 2016 , 8, 2205-2217	2.1	18
90	Protein and Peptide Conjugates for Targeting Therapeutics and Diagnostics to Specific Cells. 2016 , 475-502		
89	Pharmacokinetics and pharmacodynamics of DSTA4637A: A novel THIOMAB antibody antibiotic conjugate against Staphylococcus aureus in mice. 2016 , 8, 1612-1619		39
88	Challenges and advances in the assessment of the disposition of antibody-drug conjugates. 2016 , 37, 66-74		33
87	Targeted Bioavailability. 2016 , 49-61		
86	Unconjugated payload quantification and DAR characterization of antibody-drug conjugates using high-resolution MS. <i>Bioanalysis</i> , 2016 , 8, 1663-78	2.1	25
85	Pharmacokinetics of Antibody Drug Conjugates. 2016 , 245-266		
84	Antibody Drug Conjugates: Clinical Strategies and Applications. 2016 , 285-320		

83	Bioanalytical Strategies Enabling Successful ADC Translation. 2016 , 177-205		
82	Nonclinical Pharmacology and Mechanistic Modeling of Antibody Drug Conjugates in Support of Human Clinical Trials. 2016 , 207-243		3
81	Custom-Designed Affinity Capture LC-MS F(ab') ₂ Assay for Biotransformation Assessment of Site-Specific Antibody Drug Conjugates. <i>Analytical Chemistry</i> , 2016 , 88, 11340-11346	7.8	47
80	Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays. <i>Bioanalysis</i> , 2016 , 8, 1383-401	2.1	24
79	Chromatography-based methods for determining molar extinction coefficients of cytotoxic payload drugs and drug antibody ratios of antibody drug conjugates. 2016 , 1455, 133-139		3
78	First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 155-62	3.5	50
77	Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper. 2016 , 44, 617-23		59
76	Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates. <i>Bioanalysis</i> , 2016 , 8, 55-63	2.1	29
75	Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. <i>Analytical Chemistry</i> , 2016 , 88, 695-702	7.8	41
74	Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody-drug conjugates in biological matrices. <i>Bioanalysis</i> , 2016 , 8, 519-31	2.1	2
73	Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. 2016 , 13, 157-83		78
72	Quantitative Conjugated Payload Measurement Using Enzymatic Release of Antibody-Drug Conjugate with Cleavable Linker. 2017 , 28, 620-626		18
71	Stable and Homogeneous Drug Conjugation by Sequential Bis-Alkylation at Disulphide Bonds Using Bis-Sulphone Reagents. 2017 , 47-67		
70	Mass Spectrometry-Based Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugate Candidates During Drug Development. 2017 , 183-201		1
69	Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins. 2017 ,		3
68	Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future. <i>Journal of Clinical Pharmacology</i> , 2017 , 57 Suppl 10, S11-S25	2.9	27
67	Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. <i>Pharmaceutical Research</i> , 2017 , 34, 2579-2595	4.5	22
66	Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century. 2017 , 25, 759-780		39

65	LC-MS bioanalysis of Trastuzumab and released emtansine using nano-surface and molecular-orientation limited (nSMOL) proteolysis and liquid-liquid partition in plasma of Trastuzumab emtansine-treated breast cancer patients. 2017 , 145, 33-39		18
64	Emerging Bioanalytical Methods for the Bioanalysis of Biotherapeutics. 2017 , 180-197		
63	A single liquid chromatography-quadrupole time-of-flight mass spectrometric method for the quantification of total antibody, antibody-conjugated drug and free payload of antibody-drug conjugates. 2018 , 32, e4229		3
62	In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with Pt and Zr. 2018 , 59, 1146-1151		14
61	LC/MS Challenges in Characterizing and Quantifying Monoclonal Antibodies (mAb) and Antibody-Drug Conjugates (ADC) in Biological Samples. 2018 , 4, 45-63		13
60	Immobilization of horseradish peroxidase into cubic mesoporous silicate, SBA-16 with high activity and enhanced stability. 2018 , 116, 1304-1309		15
59	LC/MS/MS Bioanalysis of Protein-Drug Conjugates-The Importance of Incorporating Succinimide Hydrolysis Products. <i>Analytical Chemistry</i> , 2018 , 90, 5314-5321	7.8	9
58	Bioanalytical workflow for novel scaffold protein-drug conjugates: quantitation of total Centyrin protein, conjugated Centyrin and free payload for Centyrin-drug conjugate in plasma and tissue samples using liquid chromatography-tandem mass spectrometry. <i>Bioanalysis</i> , 2018 , 10, 1651-1665	2.1	10
57	2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 - PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies' inputs on bioanalysis, biomarkers and immunogenicity). <i>Bioanalysis</i> , 2018 , 10, 1897-1917	2.1	17
56	Antibody-drug conjugates: integrated bioanalytical and biodisposition assessments in lead optimization and selection. 2018 , 4,		2
55	Review of approaches and examples for monitoring biotransformation in protein and peptide therapeutics by MS. <i>Bioanalysis</i> , 2018 ,	2.1	14
54	HRP@ZIF-8/DNA Hybrids: Functionality Integration of ZIF-8 via Biomineralization and Surface Absorption. 2019 , 7, 14611-14620		21
53	Investigation of Antibody-Drug Conjugates by Mass Spectrometry. 2019 , 1140, 251-263		
52	Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. 2019 , 176, 3805-3818		9
51	Magnetic vortex gyration mediated by point-contact position. 2019 , 28, 107503		0
50	A Phase 1, Randomized, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S, an Anti- Thiomab Antibody-Antibiotic Conjugate, in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	33
49	Sample Preparation for LC-MS Bioanalysis of Antibody-Drug Conjugates. 2019 , 335-350		1
48	Method development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker drug analyte. 2019 , 411, 2587-2596		3

47	Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2. <i>Antibodies</i> , 2019 , 8,	7	23
46	Antibody-Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo. 2019 , 30, 1356-1370		9
45	Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. 2019 , 9, 17		21
44	. 2019 ,		6
43	An LC/MS based method to quantify DNA adduct in tumor and organ tissues. 2019 , 568, 1-6		3
42	Safety and Tolerability of Antibody-Drug Conjugates in Cancer. 2019 , 42, 295-314		46
41	Antibody-Drug Conjugates. <i>Methods in Molecular Biology</i> , 2020 ,	1.4	0
40	A fluorescent lateral flow biosensor for the quantitative detection of Vaspin using upconverting nanoparticles. 2020 , 226, 117610		23
39	Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical Studies. <i>Analytical Chemistry</i> , 2020 , 92, 2065-2073	7.8	15
38	Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. 2020 , 12, 1699768		12
37	Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020 , 9, 48-59	4.5	14
36	Bioanalysis of small and large molecule drugs, metabolites, and biomarkers by LC-MS. 2020 , 3-38		1
35	Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates. <i>Journal of Clinical Pharmacology</i> , 2020 , 60 Suppl 1, S105-S119	2.9	3
34	Conjugation Site Influences Antibody-Conjugated Drug PK Assays: Case Studies for Disulfide-Linked, Self-Immolating Next-Generation Antibody Drug Conjugates. <i>Analytical Chemistry</i> , 2020 , 92, 12168-12175	7.8	6
33	Analytical Methods for the Detection and Quantification of ADCs in Biological Matrices. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	6
32	Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 158, 631-639	4.9	8
31	Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 364-372	12.9	12
30	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 831-842	3.5	7

29	Quantification of an Antibody-Conjugated Drug in Fat Plasma by an Affinity Capture LC-MS/MS Method for a Novel Prenyl Transferase-Mediated Site-Specific Antibody-Drug Conjugate. <i>Molecules</i> , 2020 , 25,	4.8	10
28	Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2493-2501	3.8	2
27	Characterization of Antibody-Drug Conjugate Pharmacokinetics and in Vivo Biotransformation Using Quantitative Intact LC-HRMS and Surrogate Analyte LC-MRM. <i>Analytical Chemistry</i> , 2021 , 93, 6135-6144	7.8	7
26	Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 743-765	3.5	3
25	Clinical Pharmacology of Antibody-Drug Conjugates. <i>Antibodies</i> , 2021 , 10,	7	2
24	A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2021 , 112, 2845-2854	6.9	5
23	Development of Novel Immunoprophylactic Agents against Multidrug-Resistant Gram-Negative Bacterial Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0098521	5.9	
22	Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody-drug conjugates. <i>Bioanalysis</i> , 2021 ,	2.1	1
21	Determination of ADC Concentration by Ligand-Binding Assays. <i>Methods in Molecular Biology</i> , 2020 , 2078, 361-369	1.4	3
20	Current LC-MS-based strategies for characterization and quantification of antibody-drug conjugates. <i>Journal of Pharmaceutical Analysis</i> , 2020 , 10, 209-220	14	18
19	Ligand binding assay measurement of antibodydrug conjugates. 2016 , 110-123		1
18	Novel methods to characterize antibodydrug conjugates (DAR and PK emphasis). 2015 , 70-88		
17	A regulatory perspective: analytical component of submission packages. 2015 , 90-99		
16	Regulatory considerations. 2016 , 8-21		
15	Photoenzymatic Activity of Artificial-Natural Bienzyme Applied in Biodegradation of Methylene Blue and Accelerating Polymerization of Dopamine. <i>ACS Applied Materials & Interfaces</i> , 2021 , 13, 56191-56204	9.5	2
14	Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.. <i>Pharmaceutical Research</i> , 2022 , 39, 1	4.5	4
13	Sensitive LC-MS/MS quantification of unconjugated maytansinoid DM4 and its metabolite S-methyl-DM4 in human plasma.. <i>Bioanalysis</i> , 2022 ,	2.1	
12	Multiplexed Quantitative Analysis of Antibody-Drug Conjugates with Labile CBI-Dimer Payloads Using Immunoaffinity LC-MS/MS.. <i>Analytical Chemistry</i> , 2021 ,	7.8	0

11	Development of and Insights from Systems Pharmacology Models of Antibody-Drug Conjugates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 4.5 1	
10	Overview of the Development of Biotherapeutics and the Role of Bioanalytical Sciences. 2022 , 1-22	
9	An Introduction to Bioanalysis of Antibody-Drug Conjugates. 2022 , 49-74	o
8	ADME and DMPK considerations for the Discovery and Development of Antibody Drug Conjugates (ADCs). 1-44	o
7	AntibodyDrug Conjugates: Development and Applications. 2022 , 127-154	o
6	Construction of enzyme@glutathione hybrid metal-organic frameworks: glutathione-boosted microenvironment fine-tuning of biomimetic immobilization for improving catalytic performance. 2023 , 27, 101326	o
5	Investigation of In Vitro and In Vivo Metabolism of Amanitin in Rats Using Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometric Method. 2022 , 27, 8612	o
4	Implementation of Systematic Bioanalysis of AntibodyDrug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats. 2023 , 15, 756	o
3	Quantification of antibodydrug conjugate PYX-201 in rat and monkey plasma via ELISA and its application in preclinical studies. 2023 , 15, 43-52	o
2	Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. 14,	o
1	Bioanalysis of an antibody drug conjugate (ADC) PYX-201 in human plasma using a hybrid immunoaffinity LCMS/MS approach. 2023 , 123715	o